Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Sage Therapeutics, Inc. Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 4:58
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Sage Therapeutics, Inc. – Product Pipeline Review – 2016’, provides an overview of the Sage Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sage Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the pipeline therapeutic landscape of Sage Therapeutics, Inc. 
- The report provides overview of Sage Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Sage Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Sage Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Request a sample report @

Reasons to buy

- Evaluate Sage Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline 
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sage Therapeutics, Inc. 
- Identify potential new clients or partners in the target demographic 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Sage Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Sage Therapeutics, Inc. Snapshot 5 
Sage Therapeutics, Inc. Overview 5 
Key Information 5 
Key Facts 5 
Sage Therapeutics, Inc. – Research and Development Overview 6 
Key Therapeutic Areas 6 
Sage Therapeutics, Inc. – Pipeline Review 9 
Pipeline Products by Stage of Development 9 
Pipeline Products – Monotherapy 10 
Sage Therapeutics, Inc. – Pipeline Products Glance 11 
Sage Therapeutics, Inc. – Late Stage Pipeline Products 11 
Phase III Products/Combination Treatment Modalities 11 
Sage Therapeutics, Inc. – Clinical Stage Pipeline Products 12 
Phase II Products/Combination Treatment Modalities 12 
Phase I Products/Combination Treatment Modalities 13 
Sage Therapeutics, Inc. – Early Stage Pipeline Products 14 
IND/CTA Filed Products/Combination Treatment Modalities 14 
Preclinical Products/Combination Treatment Modalities 15 
Discovery Products/Combination Treatment Modalities 16 
Sage Therapeutics, Inc. – Drug Profiles 17 
sepranolone 17 
Product Description 17 
Mechanism of Action 17 
R&D Progress 17 
SAGE-217 20 
Product Description 20 
Mechanism of Action 20 
R&D Progress 20 
SAGE-689 21 
Product Description 21 
Mechanism of Action 21 
R&D Progress 21 
SAGE-105 22 
Product Description 22 
Mechanism of Action 22 
R&D Progress 22 
SAGE-324 23 
Product Description 23 
Mechanism of Action 23 
R&D Progress 23 
SAGE-718 24 
Product Description 24 
Mechanism of Action 24 
R&D Progress 24 
SGE-872 25 
Product Description 25 
Mechanism of Action 25 
R&D Progress 25 
Small Molecules to Agonize NMDA Receptor for Cognitive Disorders 26 
Product Description 26 
Mechanism of Action 26 
R&D Progress 26 
Small Molecules to Agonize NMDA receptor for CNS Disorders 27 
Product Description 27 
Mechanism of Action 27 
R&D Progress 27 
Small Molecules to Modulate GABAA Receptor for CNS Disorders 28 
Product Description 28 
Mechanism of Action 28 
R&D Progress 28 
Sage Therapeutics, Inc. – Pipeline Analysis 29 
Sage Therapeutics, Inc. – Pipeline Products by Target 29 
Sage Therapeutics, Inc. – Pipeline Products by Route of Administration 30 
Sage Therapeutics, Inc. – Pipeline Products by Molecule Type 31 
Sage Therapeutics, Inc. – Pipeline Products by Mechanism of Action 32 
Sage Therapeutics, Inc. – Recent Pipeline Updates 33 
Sage Therapeutics, Inc. – Dormant Projects 39 
Sage Therapeutics, Inc. – Locations And Subsidiaries 40 
Head Office 40 
Appendix 41 
Methodology 41 
Coverage 41 
Secondary Research 41 
Primary Research 41 
Expert Panel Validation 41 
Contact Us 41 
Disclaimer 42

List of Tables 
Sage Therapeutics, Inc., Key Information 5 
Sage Therapeutics, Inc., Key Facts 5 
Sage Therapeutics, Inc. – Pipeline by Indication, 2016 8 
Sage Therapeutics, Inc. – Pipeline by Stage of Development, 2016 9 
Sage Therapeutics, Inc. – Monotherapy Products in Pipeline, 2016 10 
Sage Therapeutics, Inc. – Phase III, 2016 11 
Sage Therapeutics, Inc. – Phase II, 2016 12 
Sage Therapeutics, Inc. – Phase I, 2016 13 
Sage Therapeutics, Inc. – IND/CTA Filed, 2016 14 
Sage Therapeutics, Inc. – Preclinical, 2016 15 
Sage Therapeutics, Inc. – Discovery, 2016 16 
Sage Therapeutics, Inc. – Pipeline by Target, 2016 29 
Sage Therapeutics, Inc. – Pipeline by Route of Administration, 2016 30 
Sage Therapeutics, Inc. – Pipeline by Molecule Type, 2016 31 
Sage Therapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 32 
Sage Therapeutics, Inc. – Recent Pipeline Updates, 2016 33 
Sage Therapeutics, Inc. – Dormant Developmental Projects,2016 39

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.